We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at ...

Peter Wickersham is the Vice President and General Manager of Gilead Sciences UK & Ireland, and a leader in HIV treatment, liver disease, and oncology. With over 25 years in healthcare ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Gilead forecasts it will generate between $28.2 billion and $28.6 billion in full-year sales in 2025. The company didn't reveal how the lenacapavir PrEP rollout will play into that total number ...

Feb 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday ...

The plaintiffs say they suffered unnecessary kidney and bone damage from taking one of Gilead's drugs, which could have swapped out an ingredient for a safer alternative. OAKLAND, Calif. (CN) — The ...

Dr Véronique Walsh, VP and GM at Gilead Sciences UK & Ireland, commented: “This news comes at a time when new hospitals are preparing to deliver CAR-T cell therapies and will mean that ...